Review the findings: US Safety Info: #AbbottProud #RemoteMonitoring #CardioMEMS To view or add a comment, sign in In elderly patients with NSTEMI, routine invasive strategy does not improve primary outcomes of all-cause mortality or cardiac-related death but may reduce recurrent myocardial infarction and the need for urgent revascularization To view or add a comment, sign in ConclusionsT2E is associated with sac growth and increased reinterventions, but not higher mortality
Tirzepatide: The First GLP-1/GIP Dual Agonist Tirzepatide is a dual incretin agonist that activates both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors and was developed to enhance metabolic and weight-loss outcomes beyond those achieved with GLP-1 receptor agonists alone
Whilst the abdomen and thigh are more commonly used, the back of the upper arm offers a suitable alternative for patients seeking to rotate injection sites or experiencing discomfort elsewhere
It also impairs your bodys ability to metabolize fat effectively and disrupts sleep quality, both of which undermine treatment outcomes
The combination of adequate B12 with microdose tirzepatide supports the neurological aspects of longevity protocols specifically